AngioDynamics (ANGO) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
AngioDynamics Reports Fiscal 2018 Third Quarter Financial Results
March 29, 2018 7:00 AM EDTFiscal 2018 Third Quarter Highlights
Net sales of $83.9 million, a decrease of 2.0% year over year Gross margin expanded 300 basis points year over year to 54.2% GAAP EPS of $0.37; Adjusted EPS of $0.25 per share Announced the launch of a wireless ultrasound device FDA granted Breakthrough designation to NanoKnife® System for the treatment of Stage III pancreatic cancer
LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of... More
